FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896468611> ?p ?o ?g. }

• W2896468611 endingPage "e643" @default.
• W2896468611 startingPage "e643" @default.
• W2896468611 abstract "To evaluate clinical outcomes and sites of failure for women with early stage endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy (VB) with a low dose scheme. Retrospective review identified 318 patients with FIGO stage I-II endometrioid endometrial cancer who received adjuvant VB to a dose of 24 Gy in 6 fractions from 2005-2017. Patients with less than 6 months (mo) follow-up were excluded (n=75). Dose was prescribed to cylinder surface and median activation length was 4.5 cm. Full vaginal length was treated for LVI. CT imaging was performed prior to each fraction to assess cylinder depth, diameter and vaginal length. Kaplan-Meier method was used to estimate rates of vaginal relapse (VR), pelvic nodal relapse (PNR), distant metastasis including para-aortic relapse (DM), recurrence-free survival (RFS) and overall survival (OS). Univariate analysis was performed by logrank test or Cox proportional hazards. Pre-treatment CT images were analyzed for patients with VR. Clinical characteristics of the 243 eligible patients are summarized in the Table. With median followup of 42 mo, 16 patients had recurrence at a median 21 mo after surgery. At 3 years, rates of VR, PNR, DM, RFS and OS were: 1.9%, 1.5%, 4.3%, 94.1% and 98.9%. By GOG-99 risk groups, 3-year RFS rates were 100%, 95.8% and 90% for low, low-intermediate (LIR) and high-intermediate risk (HIR) disease, respectively (p=0.19). Age, stage, BMI and LVI were not associated with RFS (all p>0.2). On pre-treatment CT images, 3 patients had distal VR at the introitus, which did not receive the prescription dose. Three patients recurred at the vaginal cuff or fornix. Patients with VR had higher BMI than those without VR (median 34 vs. 28, respectively, p=0.05). Cervical mucosal or stromal involvement was also associated with VR (3-year: 10% vs. 1% with none, p=0.06). Age, grade, LVI, and time to brachytherapy were not associated with VR (all p>0.2). The 3-year VR rates by GOG-99 risk groups were 0%, 1.4% and 3.2% for low, LIR, and HIR disease (p=0.5). By PORTEC, 3-year VR rate was 1.3% for HIR disease. Adjuvant vaginal brachytherapy with a low dose regimen results in excellent clinical outcomes for patients with early stage endometrial cancer. Patients with higher BMI and cervical extension may be at increased risk of VR, and additional study is needed to determine optimal brachytherapy treatment parameters.Abstract TU_19_3504: Table 1Age (median)63.1 years (range, 29.7 - 89.2)Body Mass Index (median)28,8 kg/m2 (range, 18.4 - 57.5)FIGO 2009 Stage IA IB II: 51% (124) 42% (103) 7% (16)GOG-99 Risk Group Low-Risk Low-intermediate risk (LIR) High-intermediate risk (HIR): 3% (7) 66% (161) 31% (75)PORTEC HIR group38% (92)Pelvic lymph node evaluation91% (221)Tumor grade 1 2 3: 34% (81) 42% (101) 24% (59)Depth of MMI (median)40% (range, 0-100)Cervical stromal involvement Cervical mucosal involvement7% (16) 2% (6)Lymphovascular invasion (LVI)20% (49) Open table in a new tab" @default.
• W2896468611 created "2018-10-26" @default.
• W2896468611 creator A5024257850 @default.
• W2896468611 creator A5034131964 @default.
• W2896468611 creator A5040332558 @default.
• W2896468611 creator A5055084299 @default.
• W2896468611 creator A5056733789 @default.
• W2896468611 creator A5057647084 @default.
• W2896468611 creator A5067173074 @default.
• W2896468611 creator A5083939916 @default.
• W2896468611 creator A5091250271 @default.
• W2896468611 date "2018-11-01" @default.
• W2896468611 modified "2023-10-01" @default.
• W2896468611 title "CT-guided Adjuvant Vaginal Brachytherapy for Endometrial Cancer: Efficacy and Sites of Failure with a Low-Dose Regimen" @default.
• W2896468611 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1751" @default.
• W2896468611 hasPublicationYear "2018" @default.
• W2896468611 type Work @default.
• W2896468611 sameAs 2896468611 @default.
• W2896468611 citedByCount "0" @default.
• W2896468611 crossrefType "journal-article" @default.
• W2896468611 hasAuthorship W2896468611A5024257850 @default.
• W2896468611 hasAuthorship W2896468611A5034131964 @default.
• W2896468611 hasAuthorship W2896468611A5040332558 @default.
• W2896468611 hasAuthorship W2896468611A5055084299 @default.
• W2896468611 hasAuthorship W2896468611A5056733789 @default.
• W2896468611 hasAuthorship W2896468611A5057647084 @default.
• W2896468611 hasAuthorship W2896468611A5067173074 @default.
• W2896468611 hasAuthorship W2896468611A5083939916 @default.
• W2896468611 hasAuthorship W2896468611A5091250271 @default.
• W2896468611 hasBestOaLocation W28964686111 @default.
• W2896468611 hasConcept C121608353 @default.
• W2896468611 hasConcept C126322002 @default.
• W2896468611 hasConcept C126838900 @default.
• W2896468611 hasConcept C126894567 @default.
• W2896468611 hasConcept C144301174 @default.
• W2896468611 hasConcept C146357865 @default.
• W2896468611 hasConcept C151730666 @default.
• W2896468611 hasConcept C2777088508 @default.
• W2896468611 hasConcept C2777416452 @default.
• W2896468611 hasConcept C2779709957 @default.
• W2896468611 hasConcept C2781413609 @default.
• W2896468611 hasConcept C2989005 @default.
• W2896468611 hasConcept C3019894029 @default.
• W2896468611 hasConcept C38180746 @default.
• W2896468611 hasConcept C50382708 @default.
• W2896468611 hasConcept C509974204 @default.
• W2896468611 hasConcept C71924100 @default.
• W2896468611 hasConcept C86803240 @default.
• W2896468611 hasConceptScore W2896468611C121608353 @default.
• W2896468611 hasConceptScore W2896468611C126322002 @default.
• W2896468611 hasConceptScore W2896468611C126838900 @default.
• W2896468611 hasConceptScore W2896468611C126894567 @default.
• W2896468611 hasConceptScore W2896468611C144301174 @default.
• W2896468611 hasConceptScore W2896468611C146357865 @default.
• W2896468611 hasConceptScore W2896468611C151730666 @default.
• W2896468611 hasConceptScore W2896468611C2777088508 @default.
• W2896468611 hasConceptScore W2896468611C2777416452 @default.
• W2896468611 hasConceptScore W2896468611C2779709957 @default.
• W2896468611 hasConceptScore W2896468611C2781413609 @default.
• W2896468611 hasConceptScore W2896468611C2989005 @default.
• W2896468611 hasConceptScore W2896468611C3019894029 @default.
• W2896468611 hasConceptScore W2896468611C38180746 @default.
• W2896468611 hasConceptScore W2896468611C50382708 @default.
• W2896468611 hasConceptScore W2896468611C509974204 @default.
• W2896468611 hasConceptScore W2896468611C71924100 @default.
• W2896468611 hasConceptScore W2896468611C86803240 @default.
• W2896468611 hasIssue "3" @default.
• W2896468611 hasLocation W28964686111 @default.
• W2896468611 hasOpenAccess W2896468611 @default.
• W2896468611 hasPrimaryLocation W28964686111 @default.
• W2896468611 hasRelatedWork W2053104579 @default.
• W2896468611 hasRelatedWork W2053331699 @default.
• W2896468611 hasRelatedWork W2075592006 @default.
• W2896468611 hasRelatedWork W2079856228 @default.
• W2896468611 hasRelatedWork W2167260654 @default.
• W2896468611 hasRelatedWork W2896468611 @default.
• W2896468611 hasRelatedWork W2984376830 @default.
• W2896468611 hasRelatedWork W3204463947 @default.
• W2896468611 hasRelatedWork W4241949839 @default.
• W2896468611 hasRelatedWork W4246030040 @default.
• W2896468611 hasVolume "102" @default.
• W2896468611 isParatext "false" @default.
• W2896468611 isRetracted "false" @default.
• W2896468611 magId "2896468611" @default.
• W2896468611 workType "article" @default.